Bayer | Pharmaceuticals

Bayer | Crop Science

Climate

Bayer Crop Science | Innovation Ecosystem

Bayer | Ophthalmology

Bayer | Consumer Health

Bayer Foundation

Bayer | Cardiopulmonary

Bayer | Oncology

Bayer | Business Consulting

Digital Hub Warsaw I Bayer

Bayer Co.Lab

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population.
At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses.
Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.

Data Privacy Statement & Imprint: https://www.bayer.com/en/glob-li-bayer-en-dps-imprint.aspx

BlueRock Therapeutics

Covercress

Bill & Melinda Gates Foundation

Temasek Holdings

Bayer

Parkinson’s disease gradually takes away a person’s ability to do what they love. We’re taking a new approach to treatment with two potentially regenerative therapies, both in various stages of clinical trials. 
 
Rather than replacing dopamine lost to Parkinson’s disease like current drugs do, cell therapy seeks to physically replace the cells that produce it. Gene therapy, on the other hand, would target existing neurons, aiming to help the brain heal itself.


#Parkinson #InnovationInHealthcare

Bayer is deeply honored to have forged a partnership with the Emirates Society of Ophthalmology, dedicated to advancing eye care solutions for patients throughout the #UAE. 
 
Hugo Hagen, Senior Bayer Representative and Country Division Head of Pharmaceutical at Bayer Middle East, along with Sheikha Dr. Noura Al Qassimi, President of the Emirates Society of Ophthalmology, came together to formalize a five-year partnership through the signing of a Memorandum of Understanding (MoU), to establish RAFEK. 

RAFEK is the first of its kind national patient centric project, aiming to address gaps in the patient journey in the field of ophthalmology, to enhance treatment outcomes using data analytics, which perfectly resonate with Bayer's overarching mission of "Health for All, Hunger for None". 

#TeamBayer #BayerMiddleEast #BayerME #HealthForAll #eso

We’re delighted that so many strong, visionary women have already found their way to us. On today's International Day of Women and Girls in Science, we would like to share the thoughts of three of our employees Fahriba Raisa, Silvia Cerezo and Satish Kamath. 
Although they are very different in terms of age, professional experience and field of work, they share one essential approach: the importance of the role of women and girls in science.

"My Journey as a Woman in Science" 
➡ https://lnkd.in/eMex3ZMc

"Science & Gender Equality – Reflections of a Surprised Uncle" 
➡ https://lnkd.in/ecMRhidx

#BayerCareer #TeamBayer #BetterTogether #BeBayer #WomenInScience #GirlsInSTEM

#AI applications bring great potential to accelerate product development and improve the way products are manufactured and delivered to customers in agriculture. 

Find out how:

G4A Girişim Hızlandırma Programı’mızın yeni dönem başvuru detayları Harvard Business Review Türkiye Dergisi’nde!

Sağlık ve tarım alanıdaki girişimcilerin başvurularını 11 Şubat’a kadar g4a.bayer.com.tr web sitemiz üzerinden bekliyoruz!

#BayerTürkiye #G4A #Girişim

We're working at full speed to redesign our company. Listen to our CEO Bill Anderson talking about what this new system essentially means.

Bei #ChronicKidneyDisease sind nicht nur die Nieren betroffen - auch das Herz kann Schaden nehmen! ❤ Eine verminderte Nierenfunktion belastet das Herz und erhöht das Risiko einer Herzinsuffizienz.
 
Erfahre mehr über Chronische Nierenerkrankungen auf unserer Website www.niereleidetleise.at
 
#ThinkKidneyCare #CKD

Inspirados na qualidade de vida dos pacientes, nossos investimentos no combate ao câncer têm sido cada vez mais expressivos. 
 
Além de iniciativas como a criação do Centro de Pesquisa e Inovação em Boston-Cambridge em junho de 2022*, também temos nos dedicado ao desenvolvimento de novos medicamentos. 
 
Cuide da sua saúde, e conte com a Bayer para continuar fomentando saúde para todos, fome para ninguém. 
 
#SeÉBayerÉBom #InspiradosNoPaciente #InspiredByYou 
 
#PraTodosVerem: esse post tem texto alternativo. 
 
*Fonte (ing.): https://lnkd.in/dxSnMtRj

In the face of major global challenges such as global warming, the COVID-19 pandemic, or the looming food shortage, scientific innovation is absolutely indispensable. And to make the best use of the expertise, brilliant minds and ideas across organizations, research collaborations are essential to achieve the scientific discoveries the world so urgently needs.

However, some view scientific partnerships, particularly between the public and private sector, with a degree of skepticism. But without trust in the scientific process and the actors involved, the best innovations are developed on a shaky foundation. Often, this distrust is rooted in the fact that people do not know enough about what these collaborations look like. 

In order to strengthen trust in science, we at Bayer set up a public transparency register: The Bayer Science Collaboration Explorer lists information on our science collaborations with universities, public research institutions & individuals. Because we want to show everyone what we do and why we are doing it. After launching the Explorer in Germany and the US, this initiative for more #transparency will now also include Swiss-based collaborations.

We invite you to explore for yourself: bayer.com/bsce

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

BAYN

COM:BAYER

Bayer AG

22.57

−0.44%

−0.10

Last Close

22.67

28/03 16:39

Market Cap

25.98B

Beta: -

Volume Today

2.59M

Avg: -

Filings Not Available